Systemic Antimycotics: Key Aspects and Perspectives | CMAC

Systemic Antimycotics: Key Aspects and Perspectives

Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(1):73-80

​ Veselov A.V.
antimycotics antifungal therapy mycoses invasive fungal infections
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(1):73-80

Abstract

Invasive fungal infections are still a growing problem of modern medicine. The prevalence of invasive fungal infections significantly increased during the last few decades concurrently with the increasing number of immunocompromised patients. The number of available and approved systemic antimycotics is not that big, and a progress in the development of new preparations does not completely conform to the rates of invasive mycoses. In this article an attempt to briefly underline the key aspects regarding current and anticipated systemic antimycotics, in order to help the clinicians to make a correct drug choice in different clinical situations, was made.

  • 1. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2:73-85.
  • 2. Nucci M., Marr K.A. Emerging fungal diseases. Clin Infect Dis 2005; 41:521-6.
  • 3. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
  • 4. Gudlaugsson O., Gillespie S., Lee K., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7.
  • 5. Morgan J., Wannemuehler K.A., Marr K.A., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective Multicenter surveillance program. Med Mycol 2005; 43(Suppl 1):S49-58.
  • 6. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002; 49(Suppl 1):7-10.
  • 7. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006; 27(Suppl 1):12-6.
  • 8. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49:31-6.
  • 9. Ng A.W., Wasan K.M., Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003; 6:67-83.
  • 10. Krupova Y., Mistrik M., Bojtarova E., et al. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support Care Cancer 2001; 9:209-10.
  • 11. Rios A., Rosenblum M., Crofoot G., et al. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J Infect Dis 1993; 168:253-4.
  • 12. Maertens J., Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005; 56(Suppl 1): i33-i38.
  • 13. Prentice A.G., Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56(Suppl 1):i17-i22.
  • 14. Charlier C., Hart E., Lefort A., et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006; 57:384- 410.
  • 15. Pfaller M.A., Diekema D.J., Rinaldi M.G., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43:5848-59.
  • 16. Herbrecht R., Denning D.W., Patterson T.F., et al. Vorico­nazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
  • 17. Keady S., Thacker M. Voriconazole in the treatment of invasive fungal infections. Intensive Crit Care Nurs 2005; 21:370-3.
  • 18. Kulemann V., Bauer M., Graninger W., Joukhadar C. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology 2005; 75:165-78.
  • 19. Hof H. A new, broad-spectrum azole antifungal: posaconazole – mechanisms of action and resistance, spectrum of activity. Mycoses 2006; 49(Suppl 1):2-6.
  • 20. Notheis G., Tarani L., Costantino F., et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006; 49(Suppl 1):37-41.
  • 21. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
  • 22. Aperis G., Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006; 15:579-602.
  • 23. Available from: http://clinicaltrials.gov/ .
  • 24. Letscher-Bru V., Herbrecht R. Caspofungin: the first repre­sentative of a new antifungal class. J Antimicrob Chemother 2003; 51:513-21.
  • 25. Villanueva A., Arathoon E.G., Gotuzzo E., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529-35.
  • 26. Mora-Duarte J., Betts R., Rotstein C., et al. Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non neutropenic patients: a multicentre randomized double-blind study. Clin Microbiol Infect 2002; 8:33-4.
  • 27. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-6.
  • 28. Groll A.H., Stergiopoulou T., Roilides E., Walsh T.J. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 2005; 14:489-509.
  • 29. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-61.
  • 30. Clemons K.V., Stevens D.A. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006; 44:69-73.
  • 31. Cohen-Wolkowiez M., Benjamin D.K. Jr., Steinbach W.J., Smith P.B. Anidulafungin: a new echinocandin for the treatment of fungal infections. Drugs Today (Barc) 2006; 42:533-44.
  • 32. Krause D.S., Simjee A.E., van Rensburg C., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770-5.
  • 33. Krause D.S., Reinhardt J., Vazquez J.A., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48:2021-4.
  • 34. Available from: www.indevus.com.
  • 35. Ghannoum MA, Isham N. Determination of minimum inhibitory concentration of Aminocandin against yeasts and filamentous fungi. J Clin Microbiol 2006; 44: 4342-4.
  • 36. Vermes A., Guchelaar H.-J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46:171-9.
  • 37. Rex J.H., Pfaller M.A. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35:982-9.
  • 38. Hosoe T., Fukushima K., Takizawa K., et al. A new antifungal macrolide, eushearilide, isolated from Eupenicillium shearii. J Antibiot (Tokyo) 2006; 59:597-600.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared